Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist.

Hepatocyte growth factor/scatter factor (HGF/SF) is a cytokine primarily produced by stromal fibroblasts and is a known angiogenic and invasion-inducing factor. It is increased in patients with breast cancer. This study examined the effect of NK4, a newly described HGF/SF antagonist, on HGF/SF-promoted growth of a human breast cancer. Both in vitro (invasion and migration assays) and in vivo (murine tumour model) methods were used to ascertain the effect of NK4 on HGF/SF from two sources: human fibroblast-derived HGF/SF and recombinant HGF/SF. In the in vitro invasion assay and migration assay, both HGF/SF and human fibroblasts, which secrete bioactive HGF/SF, increased the invasiveness and migration of the breast cancer cells (MDA MB 231). NK4 significantly reduced this invasiveness and motility. In the animal model, tumour volume and weight was significantly reduced with addition of NK4. It also suppressed HGF/SF-induced growth and markedly retarded tumour growth induced by fibroblasts (MRC5), secreting bioactive HGF/SF. Tumour angiogenesis was assessed by immunohistochemical staining of primary tissue sections using VE-cadherin (an endothelial cell specific cell-cell adhesion molecule). Again, NK4 reduced the effects of both HGF/SF and fibroblasts. We conclude that NK4 has a significant effect on the growth of human breast tumours in nude mice, particularly when stimulated by HGF/SF or fibroblasts. This may occur by decreasing angiogenesis. This gives a clear indication of the therapeutic worth of NK4.

[1]  R. Mansel,et al.  Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4 , 2000, Breast Cancer Research and Treatment.

[2]  P. Brooks.  Cell adhesion molecules in angiogenesis , 1996, Cancer and Metastasis Reviews.

[3]  W. Jiang,et al.  Regulation of angiogenesis and endothelial cell motility by matrix-bound fibroblasts , 2004, Angiogenesis.

[4]  Sheila M. Thomas,et al.  Hepatocyte Growth Factor Induces ERK-dependent Paxillin Phosphorylation and Regulates Paxillin-Focal Adhesion Kinase Association* , 2002, The Journal of Biological Chemistry.

[5]  A. Giuliano,et al.  Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. , 2001, Cancer research.

[6]  W. Jiang,et al.  Matrix‐bound fibroblasts regulate angiogenesis by modulation of VE‐cadherin , 2001, European journal of clinical investigation.

[7]  K. Matsumoto,et al.  Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. , 2001, Cancer research.

[8]  T. Nakamura,et al.  Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival , 2001, Gene Therapy.

[9]  T. Robak,et al.  Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. , 2001, European cytokine network.

[10]  K. Matsumoto,et al.  The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. , 2001, Biochemical and biophysical research communications.

[11]  C. Van Waes,et al.  Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. , 2001, Cancer research.

[12]  K. Miyazaki,et al.  Expression of the hepatocyte growth factor/c‐Met pathway is increased at the cancer front in breast carcinoma , 2001, Pathology international.

[13]  W. Jiang,et al.  Hepatocyte growth factor modulates vascular endothelial-cadherin expression in human endothelial cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  K. Matsumoto,et al.  NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells , 2001, British Journal of Cancer.

[15]  K. Matsumoto,et al.  Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. , 2000, Biochemical and biophysical research communications.

[16]  K. Matsumoto,et al.  Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells , 2000, International journal of cancer.

[17]  J. Lohr,et al.  Increased levels of serum hepatocyte growth factor in patients with end-stage renal disease. , 2000, Journal of medicine.

[18]  E. Rimm,et al.  Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma , 1999, Cancer.

[19]  Y. Cho,et al.  Significant Correlation between Serum Level of Hepatocyte Growth Factor and Progression of Gastric Carcinoma , 1999, World Journal of Surgery.

[20]  K. Matsumoto,et al.  Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  I. Bièche,et al.  Alteration of Met protooncogene product expression and prognosis in breast carcinomas. , 1999, Analytical and quantitative cytology and histology.

[22]  M. Kuwano,et al.  Biological implications of macrophage infiltration in human tumor angiogenesis , 1999, Cancer Chemotherapy and Pharmacology.

[23]  R. Day,et al.  Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis , 1999, Oncogene.

[24]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. , 1999, Critical reviews in oncology/hematology.

[25]  Kunio Matsumoto,et al.  Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor , 1998, Oncogene.

[26]  K. Matsumoto,et al.  Cooperative Interaction between α- and β-Chains of Hepatocyte Growth Factor on c-Met Receptor Confers Ligand-induced Receptor Tyrosine Phosphorylation and Multiple Biological Responses* , 1998, The Journal of Biological Chemistry.

[27]  Toshikazu Nakamura,et al.  HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor , 1997, FEBS letters.

[28]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[29]  A. N. Corps,et al.  Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c‐MET , 1997, International journal of cancer.

[30]  R. Kramer,et al.  Expression of the C‐Met/HGF receptor in human breast carcinoma: Correlation with tumor progression , 1997, International journal of cancer.

[31]  W. Jiang,et al.  Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. , 1997, Histology and histopathology.

[32]  S. Schnitt,et al.  Expression of scatter factor and c‐met receptor in benign and malignant breast tissue , 1997 .

[33]  P. Schofield,et al.  Genomic structure and chromosomal mapping of the mouse nov gene. , 1996, Genomics.

[34]  J. Folkman.  New perspectives in clinical oncology from angiogenesis research. , 1996, European journal of cancer.

[35]  A. Joseph,et al.  Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. , 1996, The American journal of pathology.

[36]  T. Nakamura,et al.  Hepatocyte growth factor induces tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and enhances cell-matrix interactions. , 1996, Oncology reports.

[37]  B. Elliott,et al.  Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. , 1996, The American journal of pathology.

[38]  M. Ogawa,et al.  Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. , 1994, Cancer research.

[39]  G. Michalopoulos,et al.  Molecular cloning and characterization of cDNA encoding mouse hepatocyte growth factor. , 1993, Biochimica et biophysica acta.

[40]  H. Kleinman,et al.  Scatter factor induces blood vessel formation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Ogawa,et al.  Immunoreactive hepatocyte growth factor is present in tissue extracts from human breast cancer but not in conditioned medium of human breast cancer cell lines. , 1993, Research communications in chemical pathology and pharmacology.

[42]  L. Naldini,et al.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.

[43]  T. Nakamura,et al.  Structure and function of hepatocyte growth factor. , 1990, Progress in growth factor research.

[44]  T. Nakamura,et al.  Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte. , 1990, Biochemical and biophysical research communications.

[45]  D. W. Vinter,et al.  Purified Scatter Factor Stimulates Epithelial and Vascular Endothelial Cell Migration , 1990, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[46]  K. Tashiro,et al.  Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.